This HTML5 document contains 91 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://www.rxlist.com/cgi/generic3/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/national-drug-code-directory/
n29http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/mixture/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/chemspider/
n9http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/patent/
n31http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n4http://linked.opendata.cz/ontology/drugbank/
n30http://www.drugs.com/cdi/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/bindingdb/
n5http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00967/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00967
rdf:type
n4:Drug
n4:description
Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
n4:dosage
n18:271B4581-363D-11E5-9242-09173F13E4C5 n18:271B4582-363D-11E5-9242-09173F13E4C5 n18:271B4583-363D-11E5-9242-09173F13E4C5 n18:271B4584-363D-11E5-9242-09173F13E4C5 n18:271B4585-363D-11E5-9242-09173F13E4C5
n4:generalReferences
# Mann RD, Pearce GL, Dunn N, Shakir S: Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000 Apr 29;320(7243):1184-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10784544 # Glass DJ, Harper AS: Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Fam Pract. 2003 Aug 13;4:10. Epub 2003 Aug 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12917016 # See S: Desloratadine for allergic rhinitis. Am Fam Physician. 2003 Nov 15;68(10):2015-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14655812 # Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18336052 # Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19539095 # DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17902729 # Bachert C, Maurer M: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010;30(2):109-22. doi: 10.2165/11530930-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20067329 # Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12642846
n4:group
investigational approved
n4:halfLife
50 hours
n4:indication
For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
n4:manufacturer
n10:271B4578-363D-11E5-9242-09173F13E4C5 n10:271B4576-363D-11E5-9242-09173F13E4C5 n10:271B4577-363D-11E5-9242-09173F13E4C5 n10:271B4575-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00967 n31:DB00967
dcterms:title
Desloratadine
adms:identifier
n15:Desloratadine n16:PA164776964 n20:46507996 n21:124087 n23:0085-1264-01 n24:110575 n25:DB00967 n26:50073179 n27:291342
n4:mechanismOfAction
Like other H1-blockers, Desloratadine competes with free histamine for binding at H<sub>1</sub>-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.
n4:packager
n10:271B4574-363D-11E5-9242-09173F13E4C5 n10:271B4572-363D-11E5-9242-09173F13E4C5 n10:271B4573-363D-11E5-9242-09173F13E4C5 n10:271B4570-363D-11E5-9242-09173F13E4C5 n10:271B4571-363D-11E5-9242-09173F13E4C5 n10:271B456E-363D-11E5-9242-09173F13E4C5 n10:271B456F-363D-11E5-9242-09173F13E4C5
n4:patent
n11:7618649 n11:5178878 n11:2294352 n11:2267136
n4:routeOfElimination
Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. Approximately 87% of a 14C-desloratadine dose was equally recovered in urine and feces.
n4:synonym
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine Descarboethoxyloratadine DESLORATADINE 8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
n12:hasAHFSCode
n19:04-08-00
n4:foodInteraction
Take without regard to meals.
n4:mixture
n22:271B456D-363D-11E5-9242-09173F13E4C5
n4:proteinBinding
82-87%
n4:synthesisReference
Zoltan Toth, "Processes for preparation of polymorphic forms of desloratadine." U.S. Patent US20040242619, issued December 02, 2004.
n28:hasConcept
n29:M0337021
foaf:page
n7:clarinex.htm n30:desloratadine.html
n4:IUPAC-Name
n5:271B458A-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B4590-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B458F-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B458C-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B458D-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B458E-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B4588-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B4586-363D-11E5-9242-09173F13E4C5 n5:271B4589-363D-11E5-9242-09173F13E4C5 n5:271B459F-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B4587-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:R06AX27
n4:H-Bond-Acceptor-Count
n5:271B4596-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B4597-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B4591-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B4592-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B4594-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B4593-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B4595-363D-11E5-9242-09173F13E4C5
n4:affectedOrganism
Humans and other mammals
n4:casRegistryNumber
100643-71-8
n4:category
n4:containedIn
n17:271B4580-363D-11E5-9242-09173F13E4C5 n17:271B457E-363D-11E5-9242-09173F13E4C5 n17:271B457F-363D-11E5-9242-09173F13E4C5 n17:271B457C-363D-11E5-9242-09173F13E4C5 n17:271B457D-363D-11E5-9242-09173F13E4C5 n17:271B457B-363D-11E5-9242-09173F13E4C5 n17:271B457A-363D-11E5-9242-09173F13E4C5 n17:271B4579-363D-11E5-9242-09173F13E4C5
n4:Bioavailability
n5:271B459B-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B459D-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B459E-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B459A-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B4599-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B459C-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B458B-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B4598-363D-11E5-9242-09173F13E4C5